Travatan is a drug owned by Alcon Pharmaceuticals Ltd. It is protected by 5 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 22, 2014. Details of Travatan's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5631287 | Storage-stable prostaglandin compositions |
Dec, 2014
(9 years ago) |
Expired
|
| US6011062 | Storage-stable prostaglandin compositions |
Dec, 2014
(9 years ago) |
Expired
|
| US5849792 | Storage-stable prostaglandin compositions |
Dec, 2014
(9 years ago) |
Expired
|
| US5889052 | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
Dec, 2014
(9 years ago) |
Expired
|
| US5510383 | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
Aug, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Travatan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Travatan's family patents as well as insights into ongoing legal events on those patents.
Travatan's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Travatan's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 22, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Travatan Generic API suppliers:
Travoprost is the generic name for the brand Travatan. 8 different companies have already filed for the generic of Travatan, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Travatan's generic
How can I launch a generic of Travatan before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Travatan's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Travatan's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Travatan -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.00004 | 28 Nov, 2008 | 1 | 22 Dec, 2014 | Extinguished |
Alternative Brands for Travatan
Travatan which is used for lowering intraocular pressure in the treatment of glaucoma and ocular hypertension., has several other brand drugs in the same treatment category and using the same active ingredient (Travoprost). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Sandoz |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Travoprost. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Travoprost, Travatan's active ingredient. Check the complete list of approved generic manufacturers for Travatan
About Travatan
Travatan is a drug owned by Alcon Pharmaceuticals Ltd. It is used for lowering intraocular pressure in the treatment of glaucoma and ocular hypertension. Travatan uses Travoprost as an active ingredient. Travatan was launched by Alcon Pharms Ltd in 2001.
Approval Date:
Travatan was approved by FDA for market use on 16 March, 2001.
Active Ingredient:
Travatan uses Travoprost as the active ingredient. Check out other Drugs and Companies using Travoprost ingredient
Treatment:
Travatan is used for lowering intraocular pressure in the treatment of glaucoma and ocular hypertension.
Dosage:
Travatan is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.004% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION/DROPS | Discontinued | OPHTHALMIC |